Tenfibgen-DMAT Nanocapsule Delivers CK2 Inhibitor DMAT to Prostate Cancer Xenograft Tumors Causing Inhibition of Cell Proliferation

Documenti analoghi

• CK2 targeted RNAi therapeutic delivered via malignant cell-directed tenfibgen nanocapsule: dose and molecular mechanisms of response in xenograft prostate tumors
  di: Ahmed, Khalil, et al.
  Pubblicazione: (2016)
• Tenfibgen Ligand Nanoencapsulation Delivers Bi-Functional Anti-CK2 RNAi Oligomer to Key Sites for Prostate Cancer Targeting Using Human Xenograft Tumors in Mice
  di: Trembley, Janeen H., et al.
  Pubblicazione: (2014)
• Mechanism and efficacy of sub-50 nm tenfibgen nanocapsules for cancer cell-directed delivery of anti-CK2 RNAi to primary and metastatic squamous cell carcinoma
  di: Unger, Gretchen M., et al.
  Pubblicazione: (2014)
• Systemic administration of antisense oligonucleotides simultaneously targeting CK2α and α′ subunits reduces orthotopic xenograft prostate tumors in mice
  di: Trembley, Janeen H., et al.
  Pubblicazione: (2011)
• CK2 Molecular Targeting—Tumor Cell-Specific Delivery of RNAi in Various Models of Cancer
  di: Trembley, Janeen H., et al.
  Pubblicazione: (2017)